Cargando…

A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD

Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI) are debilitating diseases that affect millions of individuals and have notoriously limited treatment options. One emerging therapy, non-invasive 40 Hz sensory therapy delivered through light and sound has previously shown promise in improv...

Descripción completa

Detalles Bibliográficos
Autores principales: McNett, Sienna D., Vyshedskiy, Andrey, Savchenko, Andrei, Durakovic, Danijel, Heredia, George, Cahn, Rael, Kogan, Mikhail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10379682/
https://www.ncbi.nlm.nih.gov/pubmed/37510481
http://dx.doi.org/10.3390/healthcare11142040
_version_ 1785080055392632832
author McNett, Sienna D.
Vyshedskiy, Andrey
Savchenko, Andrei
Durakovic, Danijel
Heredia, George
Cahn, Rael
Kogan, Mikhail
author_facet McNett, Sienna D.
Vyshedskiy, Andrey
Savchenko, Andrei
Durakovic, Danijel
Heredia, George
Cahn, Rael
Kogan, Mikhail
author_sort McNett, Sienna D.
collection PubMed
description Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI) are debilitating diseases that affect millions of individuals and have notoriously limited treatment options. One emerging therapy, non-invasive 40 Hz sensory therapy delivered through light and sound has previously shown promise in improving cognition in Alzheimer Disease (AD) rodent models. Small studies in humans have proven safe and tolerable, however exploration of feasibility and utility is limited. The purpose of this study is to examine the feasibility of this treatment in a human population through a smart tablet application that emits light and sound waves at 40 Hz to the user over the span of 1 h a day. Confirmation of entrainment of 40 Hz stimulation in the cerebral cortex was performed via EEG. 27 preliminary subjects with subjective cognitive complaints, Mild Cognitive Impairment, or AD were enrolled in the study; 11 participants completed 6 months of therapy. Of those that discontinued treatment, other health issues and difficulties with compliance were the most common causes. Participants were followed with Montreal Cognitive Assessment (MOCA) and Boston Cognitive Assessment (BOCA). For participants with subjective cognitive complaints, 2 of the 4 had improved MOCA score and 1 of 4 had improved BOCA score. For the participant with MCI, his MOCA score improved. For AD participants, 2 out of 6 had improved MOCA score and 3 of the 6 stayed stable, while 3 of 6 BOCA score improved. 4 of 11 participants specifically increased their MOCA scores in the Memory Index section. Of the 8 participants/caregivers able to speak to perceived usefulness of the study, 6 spoke to at least some level of benefit. Of these 6, 2 enrolled with subjective cognitive complaint, 1 had MCI, and 3 had AD. The therapy did not have reported side effects. However, those who did not finish the study experienced issues obtaining and operating a smart tablet independently as well as complying with the therapy. Overall, further exploration of this treatment modalities efficacy is warranted.
format Online
Article
Text
id pubmed-10379682
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103796822023-07-29 A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD McNett, Sienna D. Vyshedskiy, Andrey Savchenko, Andrei Durakovic, Danijel Heredia, George Cahn, Rael Kogan, Mikhail Healthcare (Basel) Article Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI) are debilitating diseases that affect millions of individuals and have notoriously limited treatment options. One emerging therapy, non-invasive 40 Hz sensory therapy delivered through light and sound has previously shown promise in improving cognition in Alzheimer Disease (AD) rodent models. Small studies in humans have proven safe and tolerable, however exploration of feasibility and utility is limited. The purpose of this study is to examine the feasibility of this treatment in a human population through a smart tablet application that emits light and sound waves at 40 Hz to the user over the span of 1 h a day. Confirmation of entrainment of 40 Hz stimulation in the cerebral cortex was performed via EEG. 27 preliminary subjects with subjective cognitive complaints, Mild Cognitive Impairment, or AD were enrolled in the study; 11 participants completed 6 months of therapy. Of those that discontinued treatment, other health issues and difficulties with compliance were the most common causes. Participants were followed with Montreal Cognitive Assessment (MOCA) and Boston Cognitive Assessment (BOCA). For participants with subjective cognitive complaints, 2 of the 4 had improved MOCA score and 1 of 4 had improved BOCA score. For the participant with MCI, his MOCA score improved. For AD participants, 2 out of 6 had improved MOCA score and 3 of the 6 stayed stable, while 3 of 6 BOCA score improved. 4 of 11 participants specifically increased their MOCA scores in the Memory Index section. Of the 8 participants/caregivers able to speak to perceived usefulness of the study, 6 spoke to at least some level of benefit. Of these 6, 2 enrolled with subjective cognitive complaint, 1 had MCI, and 3 had AD. The therapy did not have reported side effects. However, those who did not finish the study experienced issues obtaining and operating a smart tablet independently as well as complying with the therapy. Overall, further exploration of this treatment modalities efficacy is warranted. MDPI 2023-07-17 /pmc/articles/PMC10379682/ /pubmed/37510481 http://dx.doi.org/10.3390/healthcare11142040 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
McNett, Sienna D.
Vyshedskiy, Andrey
Savchenko, Andrei
Durakovic, Danijel
Heredia, George
Cahn, Rael
Kogan, Mikhail
A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
title A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
title_full A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
title_fullStr A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
title_full_unstemmed A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
title_short A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
title_sort feasibility study of alzlife 40 hz sensory therapy in patients with mci and early ad
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10379682/
https://www.ncbi.nlm.nih.gov/pubmed/37510481
http://dx.doi.org/10.3390/healthcare11142040
work_keys_str_mv AT mcnettsiennad afeasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT vyshedskiyandrey afeasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT savchenkoandrei afeasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT durakovicdanijel afeasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT herediageorge afeasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT cahnrael afeasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT koganmikhail afeasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT mcnettsiennad feasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT vyshedskiyandrey feasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT savchenkoandrei feasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT durakovicdanijel feasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT herediageorge feasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT cahnrael feasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT koganmikhail feasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad